The use of biochemical markers of bone remodeling in multiple myeloma: A report of the International Myeloma Working Group

E. Terpos, M. A. Dimopoulos, O. Sezer, G. David Roodman, N. Abildgaard, R. Vescio, P. Tosi, R. Garcia-Sanz, F. Davies, A. Chanan-Khan, A. Palumbo, P. Sonneveld, M. T. Drake, J. L. Harousseau, K. C. Anderson, B. G M Durie

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Lytic bone disease is a frequent complication of multiple myeloma (MM). Lytic lesions rarely heal and X-rays are of limited value in monitoring bone destruction during anti-myeloma or anti-resorptive treatment. Biochemical markers of bone resorption (amino- and carboxy-terminal cross-linking telopeptide of type I collagen (NTX and CTX, respectively) or CTX generated by matrix metalloproteinases (ICTP)) and bone formation provide information on bone dynamics and reflect disease activity in bone. These markers have been investigated as tools for evaluating the extent of bone disease, risk of skeletal morbidity and response to anti-resorptive treatment in MM. Urinary NTX, serum CTX and serum ICTP are elevated in myeloma patients with osteolytic lesions and correlate with advanced disease stage. Furthermore, urinary NTX and serum ICTP correlate with risk for skeletal complications, disease progression and overall survival. Bone markers have also been used for the early diagnosis of bone lesions. This International Myeloma Working Group report summarizes the existing data for the role of bone markers in assessing the extent of MM bone disease and in monitoring bone turnover during anti-myeloma therapies and provides information on novel markers that may be of particular interest in the near future.

Original languageEnglish (US)
Pages (from-to)1700-1712
Number of pages13
JournalLeukemia
Volume24
Issue number10
DOIs
StatePublished - Oct 2010
Externally publishedYes

Fingerprint

Bone Remodeling
Multiple Myeloma
Biomarkers
Bone and Bones
Bone Diseases
Serum
Bone Resorption
Collagen Type I
Matrix Metalloproteinases
Osteogenesis
Disease Progression
Early Diagnosis
Therapeutics
X-Rays
Morbidity
Survival

Keywords

  • bone markers
  • CTX
  • ICTP
  • myeloma
  • NTX

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

The use of biochemical markers of bone remodeling in multiple myeloma : A report of the International Myeloma Working Group. / Terpos, E.; Dimopoulos, M. A.; Sezer, O.; Roodman, G. David; Abildgaard, N.; Vescio, R.; Tosi, P.; Garcia-Sanz, R.; Davies, F.; Chanan-Khan, A.; Palumbo, A.; Sonneveld, P.; Drake, M. T.; Harousseau, J. L.; Anderson, K. C.; Durie, B. G M.

In: Leukemia, Vol. 24, No. 10, 10.2010, p. 1700-1712.

Research output: Contribution to journalArticle

Terpos, E, Dimopoulos, MA, Sezer, O, Roodman, GD, Abildgaard, N, Vescio, R, Tosi, P, Garcia-Sanz, R, Davies, F, Chanan-Khan, A, Palumbo, A, Sonneveld, P, Drake, MT, Harousseau, JL, Anderson, KC & Durie, BGM 2010, 'The use of biochemical markers of bone remodeling in multiple myeloma: A report of the International Myeloma Working Group', Leukemia, vol. 24, no. 10, pp. 1700-1712. https://doi.org/10.1038/leu.2010.173
Terpos, E. ; Dimopoulos, M. A. ; Sezer, O. ; Roodman, G. David ; Abildgaard, N. ; Vescio, R. ; Tosi, P. ; Garcia-Sanz, R. ; Davies, F. ; Chanan-Khan, A. ; Palumbo, A. ; Sonneveld, P. ; Drake, M. T. ; Harousseau, J. L. ; Anderson, K. C. ; Durie, B. G M. / The use of biochemical markers of bone remodeling in multiple myeloma : A report of the International Myeloma Working Group. In: Leukemia. 2010 ; Vol. 24, No. 10. pp. 1700-1712.
@article{4d111bf766374794a42fb54286657e0b,
title = "The use of biochemical markers of bone remodeling in multiple myeloma: A report of the International Myeloma Working Group",
abstract = "Lytic bone disease is a frequent complication of multiple myeloma (MM). Lytic lesions rarely heal and X-rays are of limited value in monitoring bone destruction during anti-myeloma or anti-resorptive treatment. Biochemical markers of bone resorption (amino- and carboxy-terminal cross-linking telopeptide of type I collagen (NTX and CTX, respectively) or CTX generated by matrix metalloproteinases (ICTP)) and bone formation provide information on bone dynamics and reflect disease activity in bone. These markers have been investigated as tools for evaluating the extent of bone disease, risk of skeletal morbidity and response to anti-resorptive treatment in MM. Urinary NTX, serum CTX and serum ICTP are elevated in myeloma patients with osteolytic lesions and correlate with advanced disease stage. Furthermore, urinary NTX and serum ICTP correlate with risk for skeletal complications, disease progression and overall survival. Bone markers have also been used for the early diagnosis of bone lesions. This International Myeloma Working Group report summarizes the existing data for the role of bone markers in assessing the extent of MM bone disease and in monitoring bone turnover during anti-myeloma therapies and provides information on novel markers that may be of particular interest in the near future.",
keywords = "bone markers, CTX, ICTP, myeloma, NTX",
author = "E. Terpos and Dimopoulos, {M. A.} and O. Sezer and Roodman, {G. David} and N. Abildgaard and R. Vescio and P. Tosi and R. Garcia-Sanz and F. Davies and A. Chanan-Khan and A. Palumbo and P. Sonneveld and Drake, {M. T.} and Harousseau, {J. L.} and Anderson, {K. C.} and Durie, {B. G M}",
year = "2010",
month = "10",
doi = "10.1038/leu.2010.173",
language = "English (US)",
volume = "24",
pages = "1700--1712",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - The use of biochemical markers of bone remodeling in multiple myeloma

T2 - A report of the International Myeloma Working Group

AU - Terpos, E.

AU - Dimopoulos, M. A.

AU - Sezer, O.

AU - Roodman, G. David

AU - Abildgaard, N.

AU - Vescio, R.

AU - Tosi, P.

AU - Garcia-Sanz, R.

AU - Davies, F.

AU - Chanan-Khan, A.

AU - Palumbo, A.

AU - Sonneveld, P.

AU - Drake, M. T.

AU - Harousseau, J. L.

AU - Anderson, K. C.

AU - Durie, B. G M

PY - 2010/10

Y1 - 2010/10

N2 - Lytic bone disease is a frequent complication of multiple myeloma (MM). Lytic lesions rarely heal and X-rays are of limited value in monitoring bone destruction during anti-myeloma or anti-resorptive treatment. Biochemical markers of bone resorption (amino- and carboxy-terminal cross-linking telopeptide of type I collagen (NTX and CTX, respectively) or CTX generated by matrix metalloproteinases (ICTP)) and bone formation provide information on bone dynamics and reflect disease activity in bone. These markers have been investigated as tools for evaluating the extent of bone disease, risk of skeletal morbidity and response to anti-resorptive treatment in MM. Urinary NTX, serum CTX and serum ICTP are elevated in myeloma patients with osteolytic lesions and correlate with advanced disease stage. Furthermore, urinary NTX and serum ICTP correlate with risk for skeletal complications, disease progression and overall survival. Bone markers have also been used for the early diagnosis of bone lesions. This International Myeloma Working Group report summarizes the existing data for the role of bone markers in assessing the extent of MM bone disease and in monitoring bone turnover during anti-myeloma therapies and provides information on novel markers that may be of particular interest in the near future.

AB - Lytic bone disease is a frequent complication of multiple myeloma (MM). Lytic lesions rarely heal and X-rays are of limited value in monitoring bone destruction during anti-myeloma or anti-resorptive treatment. Biochemical markers of bone resorption (amino- and carboxy-terminal cross-linking telopeptide of type I collagen (NTX and CTX, respectively) or CTX generated by matrix metalloproteinases (ICTP)) and bone formation provide information on bone dynamics and reflect disease activity in bone. These markers have been investigated as tools for evaluating the extent of bone disease, risk of skeletal morbidity and response to anti-resorptive treatment in MM. Urinary NTX, serum CTX and serum ICTP are elevated in myeloma patients with osteolytic lesions and correlate with advanced disease stage. Furthermore, urinary NTX and serum ICTP correlate with risk for skeletal complications, disease progression and overall survival. Bone markers have also been used for the early diagnosis of bone lesions. This International Myeloma Working Group report summarizes the existing data for the role of bone markers in assessing the extent of MM bone disease and in monitoring bone turnover during anti-myeloma therapies and provides information on novel markers that may be of particular interest in the near future.

KW - bone markers

KW - CTX

KW - ICTP

KW - myeloma

KW - NTX

UR - http://www.scopus.com/inward/record.url?scp=77957991625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957991625&partnerID=8YFLogxK

U2 - 10.1038/leu.2010.173

DO - 10.1038/leu.2010.173

M3 - Article

C2 - 20811404

AN - SCOPUS:77957991625

VL - 24

SP - 1700

EP - 1712

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 10

ER -